Halo Therapeutics develops highly targeted small molecule treatments using leading-edge deeptech health technologies. The company focuses on engineering breakthrough drugs with specific therapeutic intentions. This approach aims to deliver precise pharmacological effects for improved patient outcomes.
Funding
$2.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
DBFounders
Product
Problem
Viral infections pose a significant threat to public health, leading to widespread illness and mortality. Current antiviral treatments often have limited efficacy or significant side effects, and prophylactic options are lacking for many viruses. The need for targeted and effective antiviral therapies remains unmet.
Solution
Halo Therapeutics engineers targeted small molecule antiviral drugs designed to prevent viral infections and reduce the incidence of illness. The company utilizes advanced drug engineering techniques to create highly specific treatments that disrupt viral replication and prevent disease progression. Their approach focuses on developing prophylactic treatments that can be administered before or shortly after exposure to a virus, offering a proactive defense against infection. By targeting specific viral mechanisms, Halo Therapeutics aims to minimize side effects and maximize the effectiveness of their antiviral therapies.
Target Audience
Halo Therapeutics targets individuals at high risk of viral exposure, healthcare providers seeking effective prophylactic options, and public health organizations aiming to reduce the burden of viral diseases.
Features
- Targeted small molecule design for high specificity and reduced off-target effects
- Advanced drug engineering techniques to optimize antiviral activity
- Focus on prophylactic treatments to prevent viral infections